Lifevision healthcare	**LIFEVISION HEALTHCARE** **Plot No.138-139-140-141-142, EPIP, Phase-1, Jharmajri, Baddi, Distt.: Solan (H.P.)-174103** **DEPARTMENT: QUALITY CONTROL** **CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)**	Page 01 of 01

Product Name	**TUSNYL - LS**		
Generic Name	**Ambroxol Hydrochloride, Guaiphenesin & Levosalbutamol Syrup**		
Batch No.	LLD - 7072	**A.R.No.**	QC/FP/ LLD - 7072
Mfg. Date	DEC. 2023	**Batch Size**	500 Ltr.
Exp. Date	NOV. 2025	**Sample quantity**	12 X 100 ml
Date of Receipt	14-12-2023	**Date of release**	20-12-2023
Date of analysis	15-12-2023	**Mfg. Lic. No.**	MNB/09/804 & MB/09/805
Marketed by	**HINDUZA LIFE SCIENCE PVT. LTD.**		

S. No.	TEST	SPECIFICATION	OBSERVATION
1	Description	Pink coloured syrupy liquid fill in amber coloured **"100 ml"** pet bottles.	Pink coloured syrupy liquid filled in amber coloured **"100 ml"** pet bottles.
2	**Identification** **Ambroxol Hydrochloride IP** **Guaiphenesin IP** **Levosalbutamol sulphate IP**	**By UV Spectrophotometer: The absorption spectrum of standard & sample solution, in assay, exhibit maxima at about 314 nm.** **In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution.** **In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution.**	**The absorption spectrum of standard & sample solution, in assay, exhibit maxima at about 314 nm.** **In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution.** **In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution.**
3	pH	4.0 to 6.0	4.63
4	Weight per ml	1.00 to 1.30 g	1.2734 g
5	Average net volume	NLT 100 ml	100.3 ml
6	Uniformity of Volume	± 4.5 %	Within the limit
7	**Assay**		

Each 5 ml contains:	**Claim**	**Result**	**Limit**
Ambroxol Hydrochloride IP	**30 mg**	**29.867 mg (99.56 %)**	**27.0 mg to 33.0 mg (90.0 % to 110.0 %)**
Guaiphenesin IP	**50 mg**	**49.8617 mg (99.72 %)**	**45.0 mg to 55.0 mg (90.0 % to 110.0 %)**
Levosalbutamol sulphate IP Eq. to Levosalbutamol	**1 mg**	**0.9969 mg (99.69 %)**	**0.90 mg to 1.10 mg (90.0 % to 110.0 %)**

Remark: The above finished product complies to as per In House specification

	Analyzed by Officer-QC	**Checked by Executive-QC**	**Approved by Manager-QC**
Signature			For KQ
Date	20-12-2023	20-12-2023	20-12-2023